Literature DB >> 12586223

Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart.

Jean-François Bouchard1, Philippe Lépicier, Daniel Lamontagne.   

Abstract

The aim of the present study was to assess the contribution of endogenous cannabinoids in the protective effect of ischemic preconditioning on the endothelial function in coronary arteries of the rat. Isolated rat hearts were exposed to a 30-min low flow ischemia (1 ml/min) followed by 20-min reperfusion, after which the response to the endothelium-dependent vasodilator, serotonine (5-HT), was compared with that of the endothelium-independent vasodilator, sodium nitroprusside (SNP). In untreated hearts, ischemia-reperfusion diminished selectively 5-HT-induced vasodilatation, compared with time-matched sham hearts, the vasodilatation to SNP being unaffected. A 5-min zero-flow preconditioning ischemia in untreated hearts preserved the vasodilatation produced by 5-HT. Blockade of either CB(1)-receptors with SR141716A or CB(2)-receptors with SR144528 abolished the protective effect of preconditioning on the 5-HT vasodilatation. Perfusion with either palmitoylethanolamide or 2-arachidonoylglycerol 15 min before and throughout the ischemia mimicked preconditioning inasmuch as it protected the endothelium in a similar fashion. This protection was blocked by SR144528 in both cases, whereas SR141716A only blocked the effect of PEA. The presence of CB(1) and CB(2)-receptors in isolated rat hearts was confirmed by Western blots. In conclusion, the data suggest that endogenous cannabinoids contribute to the endothelial protective effect of ischemic preconditioning in rat coronary arteries.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586223     DOI: 10.1016/s0024-3205(02)02474-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  31 in total

Review 1.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 2.  CB1 cannabinoid receptor inhibition: promising approach for heart failure?

Authors:  Partha Mukhopadhyay; Rajesh Mohanraj; Sándor Bátkai; Pál Pacher
Journal:  Congest Heart Fail       Date:  2008 Nov-Dec

Review 3.  Endocannabinoids and cardiac contractile function: pathophysiological implications.

Authors:  Sándor Bátkai; Pál Pacher
Journal:  Pharmacol Res       Date:  2009-08       Impact factor: 7.658

4.  Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case report.

Authors:  Masayuki Nogi; David Fergusson; John Michael Chua Chiaco
Journal:  Hawaii J Med Public Health       Date:  2014-04

5.  Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.

Authors:  Lina T Al Kury; Oleg I Voitychuk; Keun-Hang Susan Yang; Faisal T Thayyullathil; Petro Doroshenko; Ali M Ramez; Yaroslav M Shuba; Sehamuddin Galadari; Frank Christopher Howarth; Murat Oz
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 6.  The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.

Authors:  Makenzie L Fulmer; Douglas P Thewke
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2018

7.  VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.

Authors:  Carmen Del Rio; Irene Cantarero; Belén Palomares; María Gómez-Cañas; Javier Fernández-Ruiz; Carolina Pavicic; Adela García-Martín; Maria Luz Bellido; Rafaela Ortega-Castro; Carlos Pérez-Sánchez; Chary López-Pedrera; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2018-08-23       Impact factor: 8.739

8.  Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.

Authors:  Ellen Andrag; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 9.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

10.  Activation of CB1 inhibits NGF-induced sensitization of TRPV1 in adult mouse afferent neurons.

Authors:  Z-Y Wang; T McDowell; P Wang; R Alvarez; T Gomez; D E Bjorling
Journal:  Neuroscience       Date:  2014-08-01       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.